Healthcare professional network Doximity (NYSE:DOCS) announced better-than-expected results in Q1 CY2024, with revenue up 6.4% year on year to $118.1 million. The company expects next quarter's revenue to be around $120 million, in line with analysts' estimates. It made a non-GAAP profit of $0.25 per share, improving from its profit of $0.14 per share in the same quarter last year.

Is now the time to buy Doximity? Find out by accessing our full research report, it's free.

“We were pleased to beat on our top and bottom lines, as we delivered another quarter of strong profits and record engagement,” said Jeff Tangney, co-founder and CEO of Doximity.

Founded in 2010 and named for a combination of “docs” and “proximity”, Doximity (NYSE: DOCS) is the leading social network for U.S. medical professionals.

Healthcare And Life Sciences Software

The coronavirus pandemic has underscored the importance of high-quality health infrastructure in times of crisis. Coupled with intense competition between drugmakers and the growing volume of data in the health care sector, demand for data management solutions in the healthcare space is expected to remain strong in the years ahead.

Sales Growth

As you can see below, Doximity's revenue growth has been very strong over the last three years, growing from $66.69 million in Q4 2021 to $118.1 million this quarter.

Doximity's quarterly revenue was only up 6.4% year on year, which might disappoint some shareholders. On top of that, the company's revenue actually decreased by $17.23 million in Q1 compared to the $21.67 million increase in Q4 CY2023. Regardless, we aren't too concerned because Doximity's sales seem to follow a seasonal pattern and management is guiding for revenue to rebound in the coming quarter.

Next quarter's guidance suggests that Doximity is expecting revenue to grow 10.6% year on year to $120 million, slowing down from the 19.7% year-on-year increase it recorded in the same quarter last year. For the upcoming financial year, management expects revenue to be $512 million at the midpoint, growing 7.7% year on year compared to the 13.5% increase in FY2024.

Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefitting from the rise of AI, available to you FREE via this link.

Cash Is King

If you've followed StockStory for a while, you know that we emphasize free cash flow. Why, you ask? We believe that in the end, cash is king, and you can't use accounting profits to pay the bills. Doximity's free cash flow came in at $62.31 million in Q1, up 36.6% year on year.

Doximity has generated $178.3 million in free cash flow over the last 12 months, an eye-popping 37.5% of revenue. This robust FCF margin stems from its asset-lite business model, scale advantages, and strong competitive positioning, giving it the option to return capital to shareholders or reinvest in its business while maintaining a healthy cash balance.

Key Takeaways from Doximity's Q1 Results

This was a beat and raise quarter. The company beat on revenue, adjusted EBITDA, and EPS in the quarter. Next quarter's revenue and adjusted EBITDA guidance both came in higher than Wall Street's estimates. Furthermore, the company raised its full year revenue and adjusted EBITDA guidance. Overall, this was a solid quarter for Doximity. The stock is flat after reporting and currently trades at $23.99 per share.

So should you invest in Doximity right now? When making that decision, it's important to consider its valuation, business qualities, as well as what has happened in the latest quarter. We cover that in our actionable full research report which you can read here, it's free.